Search This Blog

Friday, August 8, 2025

Officer killed in shooting outside Atlanta CDC by gunman who reportedly blamed COVID vax for illness

 A cop was killed when an unhinged gunman who blamed the COVID-19 vaccine for an apparent illness unleashed a hail of bullets outside the CDC headquarters in Atlanta on Friday, according to police and reports.

The deranged suspect, who died at the scene, opened fire after entering a building housing a CVS at Georgia’s Emory University around 4:50 p.m., forcing students to shelter in place on the last day of the summer term, according to the Atlanta Police Department.

Police Chief Darin Schierbaum said the alleged shooter sprayed multiple rounds at law enforcement and the health agency, which also houses a daycare caring for 92 children.

A bullet-ridden police vehicle near the scene of a shooting outside Emory UniversityFox 5 Atlanta
A photo taken from inside the nearby CDC building shows bullet holes in the window.via WSB-TV 2

The gunman, described as a white man, was found on the second floor of the building with a fatal gunshot wound after shooting a DeKalb County officer, Atlanta Police Chief Darin Schierbaum told reporters Friday night.

“We do not know at this time if it was an officer or it was self-inflicted,” Schierbaum said of the assailant’s gunshot.

The officer, a married father of three, was rushed to a nearby hospital, where he succumbed to his injuries, police said.

“This evening, there is a wife without a husband. There are three children, one unborn, without a father. There is a mother and a father, as well as siblings who also share in this traumatic loss,” DeKalb County CEO Lorraine Cochran-Johnson said.

An officer was wounded at the scene and later died.Getty Images

“Let’s join together to give this family the support it needs during this traumatic loss.”

Authorities confirmed that no other civilians were injured in the shooting and there is no longer an active threat.

Law enforcement sources told CNN the shooter was possibly sick, attributing the supposed ailment to the COVID-19 vaccine, according to police interviews with the suspect’s family.

The Atlanta school issued an urgent alert shortly after 5 p.m., reporting an active shooter near the Emory Point CVS on campus and urging all students to “RUN” and “HIDE.”

A rapid barrage of gunfire can be heard in horrifying social media videos as police and first responders raced to the scene.

In one video filmed by a nearby resident, eight gunshots ring out, followed by a brief pause, then more than a dozen pop in rapid succession.

“It sounded like fireworks going off, one right after the other,” Brandy Giraldo, the owner of a nearby deli, told the Associated Press.

Police were quick to arrive on the scene, surrounding the location in Emory Point.AP

A post from the school had advised students to shelter in place as the Atlanta Police Department responded to 1760 Clifton Road – close to where the CVS referred to in the bulletin is located. The lockdown was lifted by 6:30 p.m.

Police swarmed Emory Point and the main campus of the CDC, FOX 5 reported, while chilling photos shared on social media showed bullet holes piercing the windows of the health agency’s headquarters, located right next to the university. 

One police cruiser at the scene also appeared to have been hit by about a dozen gunshots to its windshield and hood.

It remains unknown how the suspect died. The condition of the injured officer is also unclear.

One photo taken at the terrifying scene shows what appears to be a man lying lifeless on a stretcher beside an ambulance surrounded by dozens of police officers. 

Police say there is no ongoing threat.AP

It remains unclear whether the person pictured is the alleged shooter.

“We are horrified by the news out of Emory University and praying for the safety of the entire campus community,” Georgia Attorney General Chris Carr said on X. 

“We stand ready to assist our law enforcement partners with whatever they may need.”

Georgia Rep. Mike Collins also shared on social media that he’s “praying for a swift end to this threat.”

https://nypost.com/2025/08/08/us-news/active-shooter-reported-at-emory-university-as-students-are-urged-to-run-hide-fight/

Trump's Greatest Deal?

 Via VigilantFox.com

President Trump is preparing to thread the needle to END the war between Russia and Ukraine.

The ONLY path forward is PEACE—and this could become the GREATEST deal he’s ever closed.

Then Rubio dropped a MASSIVE reveal: “For the first time… we have concrete examples of the kinds of things that Russia would ask for in order to end the war.”

The news hit like a shockwave just before 3:30 p.m yesterday.

Steve Witkoff, President Trump’s special envoy, had been in Moscow meeting with Vladimir Putin…but no one expected what came next.

Fox News anchor Martha MacCallum broke the story live on air:

“Thank you for being with us. We’ve got some breaking news we want to get to.”

“We want to get this in, it’s a HUGE breaking story. President Trump reportedly set to meet face-to-face with Russian president Vladimir Putin as early as next week.”

“This comes right off of Steve Witkoff’s meeting with Putin.”

Was this be the beginning of a peace deal?

According to Fox’s Peter Doocy, Putin didn’t just meet with Witkoff, but he gave him a direct message for Trump: he wants a sit-down.

A face-to-face. Wow.

“Earlier today in Moscow, Steve Witkoff was told by Vladimir Putin that Putin wants to meet at some point with Trump.”

“Witkoff then relayed that message to the president who is open to it, the possibility of a meeting as soon as next week, if the result of that meeting will be an end to the war in Ukraine.”

Doocy also said that Trump had already briefed Ukrainian President Zelenskyy and several European leaders during a phone call earlier in the day.

“We know that President Trump was on a phone call with Volodymyr Zelenskyy and some European leaders. He shared this with all of them.”

“We don’t know exactly where in the world that would be. It could be anywhere.”

The stage was being set.

Moments later, Secretary of State Marco Rubio joined Larry Kudlow on Fox Business to confirm the news.

It was real and it was happening.

Kudlow asked, “What can you tell us, Mr. Secretary?”

Rubio laid it out: “Well, Steve went over to Moscow yesterday, Steve Witkoff—and had a productive meeting in terms of what was discussed, details that perhaps hadn’t been shared before in terms of ideas about how to bring this war to an end.”

He doubled down on the administration’s sole objective:

“Let’s remind everybody that’s the goal here, the president wants to end the war.”

Rubio said that after getting the update, President Trump immediately looped in European leaders.

“The president after getting that update today convened several leaders from Europe, updated them on what happened in ‘the talks.’”

“We’re going to be having talks with our European allies and the Ukrainians as well over the next couple of days just to see what progress we can make on that side of it, and then hopefully, if things continue to progress an opportunity will present itself very soon for the president to meet both with Vladimir Putin and with President Zelensky at some point here, hopefully in the near future.”

Rubio made it clear that they weren’t there yet….peace talks take time.

“But obviously a lot has to happen before that can occur.”

He explained that if the two sides can get close enough, he believes that there’s only one man that can get them both to sign: President Trump.

“But I’ve always believed, I’ve always said this—I think the deal, there’s going to be a deal to end this war and it’ll have to require the president to come in at the end and close on it, as I’ve seen him do numerous times on trade deals as an example.”

The question now is: how close can they get both sides?

Then came a major reveal.

Rubio confirmed that for the FIRST time, they now understand what Russia actually wants to end the war.

“I think what we have is a better understanding of the conditions under which Russia would be prepared to end the war,” he said.

The challenge now is bridging that gap.

“We have to compare that to what the Ukrainians and our European allies are willing to accept.”

“If we can get those two positions close enough… then I think there’s the opportunity for the president to have a meeting that includes both Putin and Zelenskyy to try to close this thing out.”

He added, “For the first time, perhaps since this administration began, we have some concrete examples of the kinds of things that Russia would ask for in order to end the war.”

Then he said what many had already been thinking:

“We’ve got to bring the two sides and the positions close enough so that the ultimate closer, President Trump, can get involved and make it happen.”

A deal might be closer than anyone expected.

Back at the White House, President Trump was in the Oval Office with Apple CEO Tim Cook, celebrating Apple’s historic $600 billion investment into the U.S. over the next four years.

But reporters weren’t focused on tech…they wanted to know about the potential peace summit.

A reporter asked, “Have Putin and Zelensky agreed to a summit yet? And where and when would that be?”

Trump didn’t dodge. He actually leaned in.

“Well, there’s a ‘very good’ prospect that they will,” he said.

He confirmed the ball was already rolling: “And we haven’t determined where, but he had some very good talks with President Putin today.”

Then came the line that may define this moment:

“There’s a very good chance that we could be ending the, ending the round.”

Trump sees this as his shot to bring the war to a close.

But his optimism is….cautious optimism.

“The end to that road—that road was long and continues to be long, but there’s a good chance that there will be a meeting very soon.”

When asked how close he thought a deal was, Trump didn’t want to overpromise.

“Well, look—I don’t want to say. I’ve been disappointed before with this one.”

This isn’t a man guessing.

This is a man playing his cards close.

Then came the declaration.

A reporter followed up: “What was the breakthrough today? Did Vladimir Putin make some kind of concession that he hasn’t been willing to make before?”

Trump wasn’t ready to call it a breakthrough, but he made one thing clear: this wasn’t sudden.

This did not come out of thin air. It was planned.

He’s been leveraging both sides for months.

“I don’t call it a breakthrough. I mean, we’ve been working on this a long time.”

He pointed to the human cost of delay. Truly tragic.

“There are thousands of young people dying, mostly soldiers, but also, you know, missiles being hit into Kiev and other places. But in terms of soldiers, I think Russia’s lost over 20,000 since the beginning of the year. 20,000! And, I guess the estimate for Ukraine is about 9000.”

“It’s a terrible situation and we want to get it stopped.”

Then he revealed what’s been driving him all along.

“You know, we don’t have American soldiers there, but I feel I have an obligation to get it stopped.”

Trump made it clear: this isn’t his war. It started on someone else’s watch.

“This was not my war. This war would have never started. Not even a chance. And it didn’t start for four years.”

He spelled it out for the media in the room with him.

“But this is Biden’s war. This was was, on his watch. And, you know, it’s funny. We had, no land was taken from Trump. It was taken from Bush, it was taken from Biden. The whole thing would take from Biden if it weren’t for us, but it was, and it was taken by Obama.”

“Take a look at what was taken with all of the land that was taken. Nothing was taken by Russia from us. Not one ounce of land was taken.”

Then he ended with a promise.

“I’m here to get the thing over with. It would have never started if I were president. And we’re here to get it stopped and get the death stopped.”

In his mind, he’s cleaning up a war that never would’ve happened if he were still in charge.

And if this summit and eventual deal become a reality, it could mark one of the most biggest diplomatic breakthroughs in modern history…led by the man who says he feels “obligated” to bring peace.


https://www.zerohedge.com/geopolitical/trumps-greatest-deal

Blood test for multiple myeloma offers alternative to bone marrow biopsies

 Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a non-invasive alternative to traditional bone marrow biopsies.

The study was published in Nature Cancer.

"A lot of work has gone into the identification of genomic and transcriptomic features that predict worse outcome in MM, but we are still lacking the tests to measure them in our patients, said senior author, Dr. Irene M. Ghobrial. "As a clinician, this is the type of next-generation test that I would want to order for my patients."

Multiple  is a challenging bone marrow cancer, often preceded by conditions such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Traditionally, bone marrow biopsies have been used to assess risk and monitor genetic changes in these conditions. However, these biopsies are painful, infrequent, and the accompanying technique, Fluorescence in situ hybridization (FISH), often fails to provide clear results, leading to less effective risk assessment and influencing treatment decisions.

"It would be amazing if we had a blood-based test that can outperform FISH and that works in the majority of patients—we think SWIFT-seq may just be that test," said Dr. Romanos Sklavenitis-Pistofidis, co-first author.

SWIFT-seq offers an innovative alternative by allowing doctors to perform risk assessments and genetic monitoring using a simple blood test, making the process much easier and more reliable. Beyond counting CTCs, SWIFT-seq provides a detailed genetic profile, identifying key genetic changes crucial for understanding the disease. This method surpasses the accuracy of bone marrow tests like FISH. Additionally, SWIFT-seq evaluates tumor growth rates and identifies important gene patterns that can predict patient outcomes, all from a single .

"SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor's proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample," said Ghobrial.

The study involved 101 patients and healthy donors, demonstrating that SWIFT-seq successfully captured CTCs in 90% of patients with MGUS, SMM, and MM. Notably, it identified CTCs in 95% of patients with SMM and 94% of patients with newly diagnosed MM, the groups most likely to benefit from improved risk stratification and genomic surveillance. SWIFT-seq's ability to enumerate CTCs based on the tumor's molecular barcode, rather than relying on cell surface markers, sets it apart from existing methods like flow cytometry.

SWIFT-seq not only measures multiple clinically relevant features directly from a blood sample but also provides novel insights into the biology of tumor cell circulation.

"We identified a gene signature that we believe captures the tumor's circulatory capacity and may partly explain some of the unexplained mysteries of myeloma biology," said Dr. Elizabeth D. Lightbody, co-first author. "This can have a tremendous impact in how we think about curtailing tumor spread in patients with myeloma and could lead to the development of new drugs for patients."

The introduction of SWIFT-seq marks a significant advancement in myeloma diagnostics, offering a minimally invasive method to obtain multiple layers of clinically useful information from a single . This breakthrough could lead to improved patient outcomes and a deeper understanding of myeloma biology.

More information: Lightbody, E.D. et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors, Nature Cancer (2025). DOI: 10.1038/s43018-025-01006-0 www.nature.com/articles/s43018-025-01006-0


https://medicalxpress.com/news/2025-08-blood-multiple-myeloma-alternative-bone.html

Vaping cannabinoid mixtures produces chemical that destroys human tissue

 In addition to being used recreationally, marijuana and cannabidiol, or CBD, one of the cannabinoids produced by the marijuana plant, are thought to have medical benefits, such as helping with chemotherapy-induced nausea, treating epilepsy, relieving pain and helping with a variety of mental health issues.

But how people get cannabinoids into their bodies can make the difference between helping and hurting. A new study by Department of Chemistry and Biochemistry Chair and Professor Ryan Baxter and colleagues shows that conditions common to vaping marijuana or CBD oxidizes the CBD to create cannabidiol hydroxyquinone or CBD-Q. This highly toxic chemical kills human tissue.

Baxter and chemical and materials engineering professors Kara McCloskey and Roberto Andresen Eguiluz have been studying the safety profiles of components in commercially available vape cartridges to identify hazards and develop mitigation strategies.

"Under certain conditions, the cannabinoids metabolize into really toxic byproducts," Baxter said. "We have shown how that happens, why that happens and how we could prevent it. If people are going to do it anyway, could we develop an additive that prevents the formation of the toxic byproduct and protects people's lung tissues?"

The study demonstrates how storage conditions and usage vehicles degrade CBD and how QBD-Q kills cells. But the researchers have yet to conduct cell studies to identify the pathways and how CBD is metabolized by cells. Future studies will focus on how vaping conditions impact CBD stability and its degradation into toxic byproducts.

They've detailed their findings in a paper published in the journal Chemical Research in Toxicology.

Marijuana is legal in many states, and most states have no regulations regarding CBD use. Many popular brands of marijuana vapes are sold in dispensaries, and CBD vapes are commercially available in many stores, including gas stations. They're easy to use, easy to carry, produce little to no smoke and often come in tempting flavors.

But with heat and oxidative stress—conditions created when someone sucks on a vape—CBD decomposes into CBD-Q. This chemical has been used in targeted therapies to destroy malignant tumors.

"I wouldn't imagine you would want it just bathing your lungs," Baxter said.

When someone burns the  plant, several chemicals are naturally present that take some of the oxidative stress off the cannabinoids, including CBD.

"But when you add CBD to an oil suspension and put it in a vape pen, all the oxidative stress is focused on that one chemical," Baxter said. "So it's actually way worse in that setting. This context is very important because vape cartridges contain high levels of CBD and it doesn't need much heat to degrade into CBD-Q, although some cartridges heat to 200 to 300 degrees."

While CBD on its own appears to be non-toxic, the researchers also found that how it is stored contributes to the amount of CBD-Q produced.

"Luckily, most of the CBD is stored in oil-based suspensions that protect it from . But a new thing I've seen is adding CBD to beverages, such as sodas or alcoholic drinks," Baxter said.

"Those are water- or ethanol-based, and under those conditions, you end up producing more of this toxic byproduct, just upon sitting. And these things are not regulated at all by the FDA."

Baxter hopes to continue the work and investigate how vascular tissue is affected by cannabinoids.

His lab is licensed with the federal Drug Enforcement Administration to research cannabis but isn't typically involved with research into chemical compounds for vape cartridges. When Baxter saw this result, he also saw an opportunity to help make vaping safer.

"If we could discover a chemical that we could tell industry they should put in the vape cartridges to protect their consumers, I feel like industry partners would see the opportunity to advertise it as a safer product," he said.

More information: Metzli I. Montero et al, Cannabidiol Toxicity Driven by Hydroxyquinone Formation, Chemical Research in Toxicology (2025). DOI: 10.1021/acs.chemrestox.4c00448


https://medicalxpress.com/news/2025-08-vaping-cannabinoid-mixtures-chemical-destroys.html

First gene-edited islet transplant in a human passes functional trial

 Uppsala University Hospital-led investigators report that gene-edited donor islet cells survived 12 weeks inside a man with long-standing type 1 diabetes without any immunosuppressive medication.

Intensive insulin therapy can delay complications and improve life expectancy. Early-onset type 1 diabetes remains linked to reduced quality of life, serious cardiovascular risk, and shortened lifespan. Toxicity from lifelong immune suppression also drives morbidity and mortality in organ recipients.

In the study, "Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression," published in the New England Journal of Medicine, researchers conducted a first-in-human open-label trial to test whether hypoimmune-engineered islet cells could evade rejection.

A single 42-year-old man with a 37-year history of type 1 diabetes formed the cohort.

Islets from an O-matched deceased donor pancreas were isolated, dissociated, edited with CRISPR-Cas12b to knock out B2M and CIITA, lentivirally transduced to overexpress CD47, reclustered, and injected in 17 tracks into the left brachioradialis muscle under general anesthesia. No glucocorticoids, anti-inflammatory agents, or immunosuppressants were given.

Serial assays over 84 days showed strong adaptive and innate immune attacks against residual wild-type and double-knockout cells.

Hypoimmune cells triggered no T-cell activation, antibody production, or cytotoxicity. High-sensitivity C-peptide remained near or above 10 pmol/L and rose during mixed-meal testing; glycated hemoglobin fell by roughly 42%. Magnetic resonance imaging and GLP-1 receptor-targeted PET confirmed viable grafts without inflammation. Four mild adverse events were recorded, none deemed drug-related.

Daily insulin therapy continued as only 7% of a full replacement dose of beta cells was implanted. The study authors therefore describe the trial as a proof-of-survival and proof-of-function validation.

Investigators conclude that hypoimmune gene editing may eventually lead to a curative beta-cell replacement for type 1 diabetes without systemic immune suppression, a prospect that could ease daily management and reduce long-term complications for millions.

More information: Per-Ola Carlsson et al, Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2503822


https://medicalxpress.com/news/2025-08-gene-islet-transplant-human-functional.html